Current Effective Date: 12/19/24
Status: Approved
Reviewed by Medical Policy Subcommittee: 2/2/23, 12/19/24
Reviewed Dates: 11/29/22, 12/4/24

INSTRUCTIONS FOR USE DISCLAIMER:
SummaCare posts policies relating to coverage and medical necessity issues to assist members and providers in administering member benefits. These policies do not constitute a contract or agreement between SummaCare and any member or provider. The policies are guidelines only and are intended to assist members and providers with coverage issues. SummaCare is not a health care provider, does not provide or assist with health care services or treatment, and does not make guarantees as to the effectiveness of treatment administered by providers. The treatment of members is the sole responsibility of the treating provider, who is not an employee of SummaCare, but is an independent contractor in private practice. The policies posted to this site may be updated and are subject to change without prior notice to members or providers.

Medical policies in conjunction with other nationally recognized standards of care are used to make medical coverage decisions.

External Trigeminal Nerve Stimulation for ADHD Disorder **Policy**

Indication/Usage:

External or transcutaneous trigeminal nerve stimulation (TNS) is a non-invasive therapy that delivers signals to the brain via the trigeminal nerve. TNS is commonly delivered by applying stimulating electrodes on the skin of the forehead. The Monarch external Trigeminal Nerve Stimulation (eTNS) System is being developed to treat several conditions including attention deficit hyperactivity disorder (ADHD), epilepsy, and depression. In 2019 the FDA announced that they are permitting marketing of the 1st medical device to treat ADHD for NeuroSigma's Monarch external Trigeminal Nerve Stimulation (eTNS) System. This eTNS system is indicated for patients aged 7 to12 years old who are not currently taking prescription ADHD medication and is the 1st non-drug treatment for ADHD granted marketing authorization by the FDA.

.

Medical Indications for Authorization Commercial and Medicare Members

SummaCare considers external trigeminal nerve stimulation for the treatment of ADHD disorder experimental and investigational due to insufficient evidence of efficacy.

There is currently no NCD or LCD per CMS

HCPCS Code

K1016 - Transcutaneous electrical nerve stimulator for electrical stimulation of the trigeminal nerve

Limitations

There is currently insufficient evidence to support the use of external trigeminal nerve stimulation for the treatment of ADHD. The long-term effects of the device are unknown and that the device is contraindicated in patients with an implanted cardiac, neurostimulation system or implanted metallic or electronic device in their head.

Coverage Decisions

Coverage decisions made per CMS, Hayes and industry standards research

Plans Covered By This Policy

Commercial and Medicare
Considered experimental and investigational for all lines of business

Sources Reviewed

Agency for Healthcare Research and Quality (AHRQ) Website. Comparative Effectiveness Review. Attention deficit hyperactivity disorder: Effectiveness of treatment in at-risk preschoolers; long-term effectiveness in all ages; and variability in prevalence, diagnosis, and treatment. Rockville, MD: AHRQ; August 2014.

Agnew-Blais JC, Belsky DW, Caspi A, et al. Polygenic risk and the course of attentiondeficit/hyperactivity disorder from childhood to young adulthood: Findings from a nationallyrepresentative cohort. J Am Acad Child Adolesc Psychiatry. 2021; 60(9):1147-1156.

American Academy of Neurology. Assessment: efficacy of transcutaneous electric nerve stimulation in the treatment of pain in neurologic disorders (an evidence-based review). 2010 (reaffirmed 2015; 2018). Accessed Jun 10, 2021. Available at URL address: https://www.aan.com/Guidelines/home/GuidelineDetail/382

Blue Cross Blue Shield Association (BCBSA), Technology Evaluation Center (TEC). Quantitative electroencephalography as a diagnostic aid for attention deficit/ hyperactivity disorder in children. TEC Assessment Program. Chicago, IL: BCBSA; October 2014: 29.

Goode AP, Coeytaux RR, Maslow GR, et al. Nonpharmacologic treatments for attentiondeficit/hyperactivity disorder: A systematic review. Pediatrics. 2018; 141(6).

Hou YW, Xiong P, Gu X, et al. Association of serotonin receptors with attention deficit hyperactivity disorder: A systematic review and meta-analysis. Curr Med Sci. 2018; 38(3):538551.

Krull KR. Attention deficit hyperactivity disorder in children and adolescents: Overview of treatment and prognosis. UpToDate [online serial]. Waltham, MA: UpToDate; reviewed February 2013; February 2015a; February 2016; March 2019; January 2020; February 2021.

Chou DE, Gross GJ, Casadei CH, Yugrakh MS. External Trigeminal Nerve Stimulation for the Acute Treatment of Migraine: Open-Label Trial on Safety and Efficacy. Neuromodulation. 2017 Oct; 20(7):678-683

Danielson ML, Bitsko RH, Ghandour RM, Holbrook JR, Kogan MD, Blumber SJ. Prevalence of parent-reported ADHD diagnosis and associated treatment among U.S. children and adolescents. J Clin Child Adolesc Psychol. Mar-Apr 2018; 47(2):199-212.

McGough JJ, Loo SK, Sturm A, Cowen J, Leuchter AF, Cook IA. An eight-week, open-trial, pilot feasibility study of trigeminal nerve stimulation in youth with attention-deficit/hyperactivity disorder. Brain Stimul. Mar-Apr 2015; 8(2):299-304.

McGough JJ, Sturm A, Cowen J, Tung K, Salgari GC, Leuchter AF, et al. Double-blind, shamcontrolled, pilot study of trigeminal nerve stimulation for attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2019 Apr; 58(4):403-411.

Moffitt TE, Houts R, Asherson P, Belsky DW, Corcoran DL, Hammerle M, et al. Is adult ADHD a childhood-onset neurodevelopmental disorder? Evidence from a four-decade longitudinal cohort study. Am J Psychiatry. 2015 Oct; 172(10):967-77. https://www.cms.gov/